• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter Appoints Andrew Hider Chief Executive Officer

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care
    Get the next $ATS alert in real time by email

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/

    Andrew Hider Appointed Baxter's Next CEO

    Andrew Hider Appointed Baxter's Next CEO

    Since 2017, Mr. Hider has served as CEO of ATS Corporation (TSX and NYSE:ATS), an industry-leading provider of advanced automation solutions for companies in the life sciences, food and beverage, transportation, consumer products, and energy industries. Under Mr. Hider's leadership, ATS has optimized its portfolio by strategically shifting investments towards higher-growth end markets, while also delivering meaningful margin improvement. Over a five-year period ending with the company's last fiscal year, ATS's adjusted revenues have nearly doubled, representing a low-to-mid teens CAGR (compound annual growth rate) and similar adjusted EBITDA CAGR over the same period1. Since Mr. Hider's appointment in 2017, ATS's stock price has more than tripled on the TSX, significantly outperforming major indices over the same period.

    Like Baxter, ATS is a global, diversified, customer-centric company with a broad scale and range of capabilities. As of 2025, ATS operates 65+ manufacturing facilities globally. ATS's largest end-market is now its life sciences segment where its teams play a critical role enabling the development of automation solutions for medical devices, diagnostic, pharmaceutical, and laboratory operations.

    "Andrew is an exceptional leader with a strong track record of operational excellence, disciplined execution and innovation. We are excited that he will be Baxter's next CEO," said Mr. Shafer. "Andrew's leadership at global, diversified companies underscores his ability to manage complex operations and generate value for shareholders while maintaining a focus on quality and important customer-centric missions. We are confident he is the right executive to lead Baxter into its next chapter."

    "I am energized by Baxter's mission-driven culture and strong legacy of creating medically essential products that help address patients' and customers' most pressing needs," said Mr. Hider. "Baxter has undergone a significant transformation over the last few years, refocusing the company and better positioning it for the future. I look forward to partnering with the Board and working alongside my talented future colleagues to accelerate innovation, further enhance our performance and redefine healthcare delivery while driving sustainable, long-term growth."

    About Andrew Hider

    Andrew Hider brings 25 years of cross-industry experience and global expertise, a growth orientation and an operationally focused, people-centric leadership approach to Baxter. Since 2017, Mr. Hider has served as CEO and a director of ATS, an industry-leading automation solutions provider for multinational customers in markets including life sciences, food and beverage, transportation, consumer products, and energy. Mr. Hider previously served as president and CEO of the Taylor Made Group, LLC, a global leader in the supply of products and systems for marine, transportation, agriculture, and construction markets. Before Taylor Made, Mr. Hider spent 10 years at Danaher Corporation, a leading global life sciences and diagnostics innovator, in various leadership roles, including as president of Veeder-Root, a global supplier of automated tank gauges. Mr. Hider began his career with General Electric Co. in 2000, concluding his six-year tenure as president and general manager of GE Tri-Remanufacturing. In addition, he serves as a member of the board of Tennant Company, which designs, manufactures and sells cleaning products used primarily for non-residential surfaces. Mr. Hider holds a bachelor's degree in interdisciplinary engineering and management and an MBA from Clarkson University.

    About Baxter

    At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 38,000 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

    1 Source: ATS Investor Presentation (May 2025). Data is subject to disclaimers set forth in the presentation, including regarding non-lnternational Financial Reporting Standards measures used in this sentence.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250706840140/en/

    Media Contact

    Stacey Eisen, (224) 948-5353

    [email protected]

    Investor Contact

    Clare Trachtman, (224) 948-3020

    Get the next $ATS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATS
    $BAX

    CompanyDatePrice TargetRatingAnalyst
    ATS Corporation
    $ATS
    11/5/2025Sector Perform → Sector Outperform
    Scotiabank
    Baxter International Inc.
    $BAX
    10/31/2025Buy → Hold
    Argus
    Baxter International Inc.
    $BAX
    8/4/2025$25.00Buy → Hold
    Stifel
    Baxter International Inc.
    $BAX
    8/1/2025$25.00Buy → Neutral
    Goldman
    Baxter International Inc.
    $BAX
    2/26/2025$42.00Buy
    Goldman
    Baxter International Inc.
    $BAX
    2/24/2025Hold → Buy
    Argus
    Baxter International Inc.
    $BAX
    2/20/2025$39.00Overweight
    Barclays
    Baxter International Inc.
    $BAX
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $ATS
    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth in the related Offer to Purchase dated Nov. 19, 2025 (the "Offer to Purchase"). The terms of the previously announced cash tender offer by Baxter for its 2.600% Senior Unsecured Notes due 2026 (the "2026 Notes Tender Offer" and, togethe

    11/19/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Tender Offers for 2026 Notes and 2027 Notes

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the commencement of tender offers, subject to the terms and conditions described below, to purchase for cash the debt securities issued by Baxter listed in the table below (collectively, the "Securities" and each a "series"). Subject to market conditions, the tender offers are expected to be funded using a portion of the proceeds from a concurrent offering of senior unsecured notes by the Company (the "New Notes"). The Company intends to use the remaining proceeds from the concurrent public offering of the New Notes to repay other indebtedness, including any remaining 2026 Notes and its outstanding term loan cr

    11/19/25 8:54:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Declares Quarterly Dividend

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on Jan. 2, 2026, to stockholders of record as of Nov. 28, 2025. The indicated annual dividend rate equates to $0.04 per share of common stock. "As we previously announced in conjunction with third-quarter 2025 earnings, we will be reducing the quarterly dividend beginning in January 2026," said Joel Grade, Baxter's executive vice president and chief financial officer. "This action is expected to free up more than $300 million in annual cash flow, consistent with our prior commitments an

    11/11/25 4:30:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $ATS
    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $ATS
    $BAX
    SEC Filings

    View All

    SEC Form FWP filed by Baxter International Inc.

    FWP - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/19/25 5:17:33 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    11/19/25 4:21:24 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    11/19/25 9:03:26 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $ATS
    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ATS
    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    $ATS
    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EVP,Group President,Pharma Sonig Alok covered exercise/tax liability with 3,191 shares, decreasing direct ownership by 2% to 128,219 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:02:32 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    President and CEO Hider Andrew P. was granted 368,050 shares (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:01:54 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP and CFO Grade Joel T. was granted 102,712 shares, increasing direct ownership by 86% to 222,560 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:01:18 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    ATS Announces CEO Departure

    ATS Corporation (TSX:ATS) (NYSE:ATS) ("ATS" or the "Company") today announced that Andrew Hider will be stepping down from his role as Chief Executive Officer of the Company and from its Board of Directors (the "Board") to pursue a new leadership opportunity outside the automation industry. The effective date for Mr. Hider's departure from the Company is expected to be by the end of August on a date to be determined by the Board. As a result of the foregoing, Mr. Hider will be withdrawing his candidacy for election to the Board at the Company's upcoming Annual General Meeting ("AGM") being held on August 7th, 2025. The Company will be filing an amendment to its management information circul

    7/7/25 8:30:00 AM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    ATS Corp upgraded by Scotiabank

    Scotiabank upgraded ATS Corp from Sector Perform to Sector Outperform

    11/5/25 3:58:28 PM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $ATS
    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ATS Corporation

    SC 13G/A - ATS Corp /ATS (0001394832) (Subject)

    11/13/24 10:27:59 AM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by ATS Corporation

    SC 13G/A - ATS Corp /ATS (0001394832) (Subject)

    11/13/24 9:14:58 AM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    $ATS
    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth in the related Offer to Purchase dated Nov. 19, 2025 (the "Offer to Purchase"). The terms of the previously announced cash tender offer by Baxter for its 2.600% Senior Unsecured Notes due 2026 (the "2026 Notes Tender Offer" and, togethe

    11/19/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Declares Quarterly Dividend

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on Jan. 2, 2026, to stockholders of record as of Nov. 28, 2025. The indicated annual dividend rate equates to $0.04 per share of common stock. "As we previously announced in conjunction with third-quarter 2025 earnings, we will be reducing the quarterly dividend beginning in January 2026," said Joel Grade, Baxter's executive vice president and chief financial officer. "This action is expected to free up more than $300 million in annual cash flow, consistent with our prior commitments an

    11/11/25 4:30:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    ATS Reports Second Quarter Fiscal 2026 Results

    ATS Corporation (TSX and NYSE:ATS) ("ATS" or the "Company") today reported its financial results for the three and six months ended September 28, 2025. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. Second quarter highlights: Revenues increased 18.9% year over year to $728.5 million. Net income was $33.6 million compared to net loss of $0.9 million a year ago. Basic earnings (loss) per share were 34 cents, compared to (1) cent a year ago. Adjusted EBITDA1 was $103.7 million compared to $78.3 million a year ago. Adjusted basic earnings per share1 were 45 cents compared to 25 cents a year ago. Order Bookings2 were $734

    11/5/25 6:00:00 AM ET
    $ATS
    Industrial Machinery/Components
    Industrials